There's no point in trying to explain this to Average Al. I've tried on many occasions, linked him the guidelines etc. Some people just aren't interested in fact. Although others here might be interested...
In FY2024, IMU acquired Azer-Cel. A US developed asset with trial and manufacturing being entirely conducted in the US. IMU's R&D spend during FY24 was AU$86m, at least US$21m of which was up front costs related to the acquisition (there are rolling cots associated with the Azer-Cel acquisition, you certainly can't claim R&D rebates on strategic acquisitions).
Despite this spend, IMU have forecast their FY rebate at $4.6m (although there is an impairment of an additional $4.5m that has not been addressed by the company).
There's probably a number of reasons IMU will have brought the Azer-Cel trial to Australia, two of them are:
1. Significant cost savings. 2. To further leverage the R&D rebate.
Just as an aside; IMU are hopeful to complete the P1b of Azer-Cel this year. That's another US$8m to go to Precision that they just don't have. More dilution?
IMU Price at posting:
2.1¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)